Pharmacology and regulation of the neuronal dopamine transporter

European Journal of Pharmacology

Volumn 324, Issue 1, 1997, Pages 1-10

  Reith, Maarten E A ^a   Xu, Cen ^a   Chen, Nian Hang ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Arachidonic acid; Dopamine transporter; Drug abuse; Parkinson's disease; Protein kinase C; WIN 35,428 binding

Indexed keywords

1 [1 (2 BENZO[B]THIENYL)CYCLOHEXYL]PIPERIDINE; 1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; ARACHIDONIC ACID; BENZOCAINE; COCAINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; PROTEIN KINASE C;

ANIMAL TISSUE; DOPAMINERGIC SYSTEM; ION CURRENT; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVIEW;

BINDING, COMPETITIVE; BRAIN DISEASES; CARRIER PROTEINS; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; ION TRANSPORT; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURONS; RECEPTORS, DOPAMINE D2; SECOND MESSENGER SYSTEMS;

EID: 0031564599     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)00065-4     Document Type: Review

References (95)

1. Asaoka, Y., Nakamura, S., Yoshida, K., Nishizuka, Y., 1992. Protein kinase C, calcium and phospholipid degradation. Trends Biochem. Sci. 17, 414-417.
2. Bannon, M.J., Granneman, J.G., Kapatos, G., 1995. The dopamine transporter. Potential involvement in neuropsychiatric disorders. In: Bloom, F.E. and Kupfer, D.J. (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, NY, pp. 179-188.
3. 3H]GBR-12935: a specific high affinity ligand for labeling the dopamine transport complex. Eur. J. Pharmacol. 107, 289-290.
4. Berger, S.P., Farrell, K., Conant, D., Kempner, E.S., Paul, S.M., 1994. Radiation inactivation studies of the dopamine reuptake transporter protein. Mol. Pharmacol. 46, 726-731.
5. 3H]GBR 12783 to a site associated with the dopamine uptake carrier. J. Neurochem. 50, 759-765.
6. 3H]mazindol. J. Pharmacol. Exp. Ther. 253, 1206-1214.
7. 2+. Eur. J. Pharmacol. 266, 87-97.
8. Buck, K.J., Amara, S.G., 1994. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. USA 91, 12584-12588.
9. Buck, K.J., Amara, S.G., 1995. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol. Pharmacol. 48, 1030-1037.
10. Bugnon, O., Ofori, S., Schorderet, M., 1995. Okadaic acid modulates exocytotic and transporter-dependent release of dopamine in bovine retina in vitro. Naunyn-Schmiedeberg's Arch. Pharmacol. 351, 53-59.
11. 3H]cocaine in striatum and its relationship to the dopamine transporter. Membr. Biochem. 7, 87-106.
12. Carlsson, M., Carlsson, A., 1990. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13, 272-276.
13. Carroll, F.I., Scheffel, U., Dannals, R.F., Boja, J.W., Kuhar, M.J., 1995. Development of imaging agents for the dopamine transporter. Med. Res. Rev. 15, 419-444.
14. Chen, N.H., Reith, M.E.A., 1997. Role of axonal and somatodendritic monoamine transporters in action of uptake blockers. In: Reith, M.E.A. (Ed.), Neurotransmitter Transporters: Structure, Function and Regulation. Humana Press, Clifton, NJ, pp. 345-391.
15. 125I]3β-(iodophenyl)tropan-2β-carboxylic acid isopropyl ester to the dopamine transporter at a physiologically relevant temperature: mutually exclusive binding and different ionic requirement for various uptake blockers and substrates. Synapse 25, 155-162.
16. Cook Jr., E.H., Stein, M.A., Krasowski, M.D., Cox, N.J., Olkon, D.M., Kieffer, J.E., Leventhal, B.L., 1995. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56, 993-998.
17. Coyle, J.T., Snyder, S.H., 1969. Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J. Pharmacol. Exp. Ther. 170, 221-231.
18. Daniels, J., Williams, J., Asherson, P., McGuffin, P., Owen, M., 1995. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am. J. Med. Gen. 60, 85-87.
19. Davis, S., Wang, J.B., Uhl, G.R., 1994. The phenyl ring of tyrosine 250 of the dopamine transporter is required for high-affinity binding of cocaine analogs. Soc. Neurosci. Abstr. 20, 922.
20. Di Chiara, G., North, R.A., 1992. Neurobiology of opiate abuse. Trends Pharmacol. Sci. 13, 185-193.
21. 3H]GBR 12935 to rat and bovine striata. Membr. Biochem. 10, 129-144.
22. Eshleman, A.J., Neve, R.L., Janowsky, A., Neve, K.A., 1995. Characterization of a recombinant human dopamine transporter in multiple cell lines. J. Pharmacol. Exp. Ther. 274, 276-283.
23. Gelernter, J., Kranzler, H.R., Satel, S.L., Rao, P.A., 1994. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 11, 195-200.
24. Giambalvo, C.T., 1992. Protein kinase C and dopamine transport. 1. Effects of amphetamine in vivo. Neuropharmacology 31, 1201-1210.
25. Giros, B., Caron, M.G., 1993. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14, 43-49.
26. Giros, B., El Mestikawy, S., Godinot, N., Zheng, K., Han, H., Yang-Feng, T., Caron, M.G., 1992. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42, 383-390.
27. Giros, B., Wang, Y.M., Suter, S., McLeskey, S.B., Pifl, C., Caron, M.G., 1994. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269, 15985-15988.
28. Giros, B., Jaber, M., Jones, S.R., Wightman, R.M., Caron, M.G., 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
29. Grenhoff, J., Svensson, T.H., 1993. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur. J. Pharmacol. 233, 79-84.
30. Gu, H.H., Rudnick, G., 1996. A thermodynamic study of the dopamine transporter ion-coupling mechanism. Soc. Neurosci. Abstr. 22, 370.
31. Gu, H., Wall, S.C., Rudnick, G., 1994. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269, 7124-7130.
32. 3H]GBR 12783 binding to the dopamine neuronal carrier. Eur. J. Pharmacol. 301, 195-202.
33. Hollenberg, M.D., Cuatrecasas, P., 1979. Distinction of receptor from nonreceptor interactions in binding studies. In: O'Brien, R.D. (Ed.), The Receptors: A Comprehensive Treatise. Plenum Press, New York, NY, pp. 193-214.
34. max. J. Neurochem. 68, 225-232.
35. Iversen, L.L., 1971. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmacol. 41, 571-591.
36. 3H]Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol. Pharmacol. 26, 35-44.
37. Jess, U., Betz, H. and Schloss, P., 1996. The membrane-bound rat serotonin transporter, SERT1, is an oligomeric protein. FEBS Lett. 394, 44-46.
38. 3H]mazindol binding sites from alkylation by N-ethylmaleimide. Eur. J. Pharmacol. 227, 411-415.
39. Kadowaki, K., Hirota, K., Koike, K., Ohmichi, M., Kiyama, H., Miyake, A., Tanizawa, O., 1990. Adenosine 3′,5′-cyclic monophosphate enhances dopamine accumulation in rat hypothalamic cell culture containing dopaminergic neurons. Neuroendocrinology 52, 256-261.
40. Kennedy, L.T., Hanbauer, I., 1983. Sodium-sensitive cocaine binding to rat striatal membrane: possible relationship to dopamine uptake sites. J. Neurochem. 41, 172-178.
41. Kilty, J.E., Lorang, D., Amara, S.G., 1991. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254, 578-579.
42. Kitayama, S., Shimada, S., Xu, H., Markham, L., Donovan, D.M., Uhl, G.R., 1992. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. USA 89, 7782-7785.
43. + transport. Synapse 15, 58-62.
44. Kitayama, S., Dohi, T., Uhl, G.R., 1994. Phorbol esters alter functions of the expressed dopamine transporter. Eur. J. Pharmacol. 268, 115-119.
45. Krueger, B.K., 1990. Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J. Neurochem. 55, 260-267.
46. 3H]imipramine binding in rat hypothalamus: association with uptake of serotonin but not of norepinephrine. Science 210, 1133-1135.
47. Langston, J.W., 1985. Mechanism of MPTP toxicity: more answers, more questions. Trends Pharmacol. Sci. 6, 375-378.
48. L'hirondel, M., Cheramy, A., Godeheu, G., Glowinski, J., 1995. Effects of arachidonic acid on dopamine synthesis, spontaneous release, and uptake in striatal synaptosomes from the rat. J. Neurochem. 64, 1406-1409.
49. 123I]β-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology 122, 358-362.
50. Mash, D.C., Staley, J.K., 1997. The dopamine transporter in human brain. In: Reith, M.E.A. (Ed.), Neurotransmitter Transporters: Structure, Function, and Regulation. Humana Press, Totowa, NJ, pp. 315-343.
51. McElvain, J.S., Schenk, J.O., 1992. A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem. Pharmacol. 43, 2189-2199.
52. 2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J. Neurochem. 61, 764-767.
53. Miller, J.W., Kleven, D.T., Domin, B.A., Fremeau Jr., A., 1997. Cloned sodium- (and chloride-) dependent high-affinity transporters for GABA, glycine, proline, betaine, taurine, and creatine. In: Reith, M.E.A. (Ed.), Neurotransmitter Transporters: Structure, Function, and Regulation. Humana Press, Totowa, NJ, pp. 101-149.
54. Milner, H.E., Beliveau, R., Jarvis, S.M., 1994. The in situ size of the dopamine transporter is a tetramer as estimated by radiation inactivation. Biochim. Biophys. Acta 1190, 185-187.
55. Nishizuka, Y., 1995. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 9, 484-496.
56. 2 antagonist pimozide inhibits up-regulation of dopamine release and uptake induced by repeated cocaine. J. Neurochem. 60, 376-379.
57. Patel, A.P., 1997. Neurotransmitter transporter proteins. In: Reith, M.E.A. (Ed.), Neurotransmitter Transporters: Structure, Function, and Regulation. Humana Press, Totowa, NJ, pp. 241-262.
58. Patel, A., Uhl, G., Kuhar, M.J., 1993. Species differences in dopamine transporters: Postmortem changes and glycosylation differences. J. Neurochem. 61, 496-500.
59. Povlock, S., Amara, S.G., 1997. The structure and function of norepinephrine, dopamine, and serotonin transporters. In: Reith, M.E.A. (Ed.), Neurotransmitter Transporters: Structure, Function, and Regulation. Humana Press, Totowa, NJ, pp. 1-28.
60. Reith, M.E.A., 1988. Cocaine receptors on monoamine transporters and sodium channels. NIDA Res. Monogr. 88, 23-43.
61. 3H]tropane to the dopamine uptake carrier. J. Neurochem. 61, 167-177.
62. Reith, M.E.A., Selmeci, G., 1992. Radiolabeling of dopamine uptake sites in mouse striatum: comparison of binding sites for cocaine, mazindol, and GBR 12935. Naunyn-Schmiedeberg's Arch. Pharmacol. 345, 309-318.
63. 3H]cocaine binding in central nervous system of mouse. Life Sci. 27, 1055-1062.
64. 3H]cocaine binding in brain is associated with serotonergic neurons. Mol. Pharmacol. 23, 600-606.
65. Reith, M.E.A., Meisler, B.E., Sershen, H., Lajtha, A.
66. Reith, M.E.A., Xu, C., Coffeyice, K.C., Jacobson, A.E., 1992. Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur. J. Pharmacol. 227, 417-425.
67. 3H]WIN 35,428) binding. Biochem. Pharmacol. 52, 1435-1446.
68. Reith, M.E.A., Xu, C., Zhang, L., Coffey, L.L., 1996b. Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter. Naunyn-Schmiedeberg's Arch. Pharmacol. 354, 295-304.
69. Richelson, E., Pfenning, M., 1984. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur. J. Pharmacol. 104, 277-286.
70. Ritchie, J.M. and Greengard, P., 1966. On the mode of action of local anesthetics. Annu. Rev. Pharmacol. 6, 405-430.
71. Ritz, M.C., Lamb, R.J., Goldberg, S.R., Kuhar, M.J., 1987. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219-1223.
72. Rudnick, G., 1997. Mechanisms of biogenic amine neurotransmitter transporters. In: Reith, M.E.A. (Ed.), Neurotransmitter Transporters: Structure, Function, and Regulation. Humana Press, Totowa, NJ, pp. 73-100.
73. Rudnick, G., Clark, J., 1993. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim. Biophys. Acta 1144, 249-263.
74. 3H]methylphenidate to the dopamine transporter. Synapse 16, 188-194.
75. Seeman, P., Niznik, H.B., 1990. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 4, 2737-2744.
76. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38, 589-598.
77. Shank, R.P., Gardocki, J.F., Schneider, C.R., Vaught, J.L., Setler, P.E., Maryanoff, B.E., McComsey, D.F., 1987. Preclinical evaluation of McN-5707 as a potential antidepressant. J. Pharmacol. Exp. Ther. 242, 74-84.
78. Shimada, S., Kitayama, S., Lin, C.L., Patel, A., Nanthakumar, E., Gregor, P., Kuhar, M., Uhl, G., 1991. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254, 576-578;
79. Shimada, S., Kitayama, S., Lin, C.L., Patel, A., Nanthakumar, E., Gregor, P., Kuhar, M., Uhl, G., 1991. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254, 576-578; Science 255 (1992) 1195 (Erratum).
80. 3H-dopamine uptake into rat brain homogenates. J. Pharmacol. Exp. Ther. 165, 78-86.
81. Tanaka, T., Vincent, S.R., Nomikos, G.G., Fibiger, H.C., 1992. Effect of quinine on autoreceptor-regulated dopamine release in the rat striatum. J. Neurochem. 59, 1640-1645.
82. Uhl, G.R., Kitayama, S., 1993. A cloned dopamine transporter. Potential insights into Parkinson's disease pathogenesis. Adv. Neurol. 60, 321-324.
83. Usdin, T.B., Mezey, E., Chen, C., Brownstein, M.J., Hoffman, B.J., 1991. Cloning of the cocaine-sensitive bovine dopamine transporter. Proc. Natl. Acad. Sci. USA 88, 11168-11171.
84. Vaughan, R.A., 1995. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping. Mol. Pharmacol. 47, 956-964.
85. Wheeler, D.D., Edwards, A.M., Chapman, B.M., Ondo, J.G., 1994. Effects of cocaine on sodium dependent dopamine uptake in rat striatal synaptosomes. Neurochem. Res. 19, 49-56.
86. White, F.J., 1990. Electrophysiological basis of the reinforcing effects of cocaine. Behav. Pharmacol. 1, 303-315.
87. Wise, R.A., 1978. Catecholamine theories of reward: a critical review. Brain Res. 152, 215-247.
88. Wise, R.A., Bozarth, M.A., 1987. A psychomotor stimulant theory of addiction. Psychol. Rev. 94, 469-492.
89. Xu, C., Reith, M.E.A., 1996. Modeling of the pH dependence of the binding of WIN 35,428 to the dopamine transporter in rat striatal membranes: is the bioactive form positively charged or neutral? J. Pharmacol. Exp. Ther. 278, 1340-1348.
90. Xu, C., Coffey, L.L., Reith, M.E.A., 1995. Translocation of dopamine and binding of 2β-carbomethoxy-β-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Biochem. Pharmacol. 49, 339-350.
91. 3H]WIN 35,428 binding. Naunyn-Schmiedeberg's Arch. Pharmacol. 355, 64-73.
92. Zhang, L., Reith, M.E.A., 1996. Regulation of the functional activity of the human dopamine transporter by the arachidonic acid pathway. Eur. J. Pharmacol. 315, 345-354.
93. Zhang, L., Coffey, L.L., Reith, M.E.A., 1997. Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem. Pharmacol. (in press).
94. Zhu, S.-J., Sonders, M.S., Amara, S.G., Kavanaugh, M.P., Zahniser, N.R., 1995. Uptake of dopamine by the cloned human dopamine transporter is voltage-dependent in Xenopus oocytes. Soc. Neurosci. Abstr. 21, 375.
95. Zimanyi, I., Lajtha, A., Reith, M.E.A., 1989. Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. Naunyn-Schmiedeberg's Arch. Pharmacol. 340, 626-632.